PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 5, 2026Journal of the Endocrine Society1 citationsOpen Access

Comprehensive Genetic Rescreening Improves Diagnostic Yield in Congenital Hyperinsulinism

View Full Paper
RMRobert MasseyJHJayne A L HoughtonJBJasmin J Bennett

Key Points

  • This research evaluates whether genetic rescreening can improve diagnosis in congenital hyperinsulinism patients with previously unresolved genetic causes.
  • Twenty-seven probands from Finland with unresolved congenital hyperinsulinism were rescreened.
  • Targeted genetic analysis focused on coding regions of 18 known HI genes and 5 non-coding regions.
  • Participants had a history of 3 previous negative or inconclusive genetic tests.
  • Genetic rescreening provided new insights in 22% of the cases.
  • Definitive diagnoses were established in 15% (4 out of 27) of participants.
  • New findings included non-coding variants in ABCC8, HK1, and SLC16A1 genes, and a GCK mosaic variant.

Abstract

Abstract Context Recent genetic discoveries in congenital hyperinsulinism (HI) and advances in sequencing technology suggest that the diagnostic yield may be improved by rescreening in people with genetically unsolved HI. Objective To evaluate this hypothesis in a nationwide cohort of individuals with a historical diagnosis of HI of unknown genetic cause. Methods Twenty-seven probands, representing 77% of the genetically unsolved HI cases in Finland, underwent rescreening which targeted the coding regions of 18 known HI genes, and 5 relevant non-coding regions. The median age of the cohort was 21 years (range, 4–44 years). Participants had previously undergone a median of 3 genetic tests (range, 1–4), all of which yielded negative (n=17) or inconclusive (n=10) results. Results Genetic rescreening was informative in 22% (6 of 27) of cases. Definitive genetic diagnoses were established in 4 (15%) participants. These included the detection of non-coding variants in the ABCC8, HK1, and SLC16A1 genes, and a GCK mosaic variant (8% allele fraction). In 2 (7%) cases, revised genetic results but did not provide a definitive genetic diagnosis. Conclusions In this Finnish cohort, rescreening with a comprehensive gene panel provided new or revised diagnoses in 22% of cases, informing on medical management and recurrence risk. These findings emphasize the importance of regularly updating genetic testing strategies and highlight the clinical value of re-evaluating the need for rescreening in genetically unexplained HI cases even following clinical remission.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Massey et al. (2026) studied this question.

synapsesocial.com/papers/69a91dc3d6127c7a504c0f55https://doi.org/10.1210/jendso/bvag047
Ask AI
Helpful
Bookmark
Share
View Full Paper